SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025.

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer ...

--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (SAGE), today reported ... Collaboration revenue represents 50% of the net revenue recorded when Biogen ships ZURZUVAE to the distributors.

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1. ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

Sales are likely to have improved sequentially in the first quarter. Biogen has a collaboration with Sage Therapeutics SAGE for Zurzuvae. Biogen and Sage equally share profits and losses for the ...

12:42 PM ESTHealth Care Biogen offers to buy out Sage Therapeutics Biogen offers to buy out Sage Therapeutics ...